<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098522</url>
  </required_header>
  <id_info>
    <org_study_id>RVLO 121-05</org_study_id>
    <nct_id>NCT05098522</nct_id>
  </id_info>
  <brief_title>Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Allergen Challenge Trial of 6 Repeat Doses of IRL201104 in Adult Participants With Seasonal Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revolo Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revolo Biotherapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this allergen challenge study is to assess the efficacy of IRL201104 compared&#xD;
      with placebo in adult participants with seasonal allergic rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean diameter of the Intradermal Challenge (IDC) Late Phase Response (LPR) on Day 84 as the primary analysis measured 8 hours post-challenge after 10 weeks of treatment with IRL201104 compared with placebo.</measure>
    <time_frame>Day 84</time_frame>
    <description>An analysis of covariance (ANCOVA) will be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The largest diameter (mm) of the IDC Early Phase Response (EPR) at 20 minutes after 10 weeks of treatment with IRL201104 compared with placebo</measure>
    <time_frame>Day 84</time_frame>
    <description>An analysis of covariance (ANCOVA) will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of suppression of the IDC EPR and LPR at 8 hours over time after 10 weeks of treatment with IRL201104 compared with placebo</measure>
    <time_frame>Day 84</time_frame>
    <description>An analysis of covariance (ANCOVA) will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin prick test EPR endpoint titration of Grass Soluprick after 10 weeks of treatment with IRL201104 compared with placebo.</measure>
    <time_frame>Day 84</time_frame>
    <description>An analysis of covariance (ANCOVA) will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The weighted average of the TNSS per hour following NAC after 10 weeks of treatment with IRL201104 compared with placebo.</measure>
    <time_frame>Day 84</time_frame>
    <description>An analysis of covariance (ANCOVA) will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in peak nasal inspiratory flow (PNIF) after the NAC after 10 weeks of treatment with IRL201104 compared with placebo.</measure>
    <time_frame>Day 84</time_frame>
    <description>An analysis of covariance (ANCOVA) will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IRL20114 levels.</measure>
    <time_frame>Day 56</time_frame>
    <description>IRL201104 plasma levels will be summarized for each blood sample draw timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Blood pressure</measure>
    <time_frame>Day 84</time_frame>
    <description>Summary statistics, by and across randomized treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Pulse rate</measure>
    <time_frame>Day 84</time_frame>
    <description>Summary statistics, by and across randomized treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: oral body temperature</measure>
    <time_frame>Day 84</time_frame>
    <description>Summary statistics, by and across randomized treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: respiration rate</measure>
    <time_frame>Day 84</time_frame>
    <description>Summary statistics, by and across randomized treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Day 84</time_frame>
    <description>Summary statistics, by and across randomized treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent antidrug antibody (ADA) responses</measure>
    <time_frame>Day 84</time_frame>
    <description>Tabulated and presented as the number and percentage of participants exhibiting the response within each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory: Biochemistry</measure>
    <time_frame>Day 84</time_frame>
    <description>Glucose, liver function tests, urea, and electrolytes will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory: Haematology</measure>
    <time_frame>Day 84</time_frame>
    <description>Full blood count variables will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Arm 1: IRL201104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IRL201104</intervention_name>
    <description>lyophilised powder for reconstitution for IV dosing</description>
    <arm_group_label>Arm 1: IRL201104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for IRL201104</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 to 65 years old, inclusive, at time of signing the informed consent&#xD;
             form (ICF).&#xD;
&#xD;
          2. Weight â‰¥ 50 kg, body mass index within the range 19 to 30 kg/m2.&#xD;
&#xD;
          3. A clinical history of grass pollen-induced allergic rhinitis for at least 2 years with&#xD;
             peak symptoms in May, June, or July.&#xD;
&#xD;
          4. A clinical history of moderate to severe rhinitis symptoms interfering with usual&#xD;
             daily activities or with sleep as defined according to the ARIA classification of&#xD;
             rhinitis (Bousquet, Khaltaev et al 2008)&#xD;
&#xD;
          5. A clinical history of rhinitis for at least 2 years requiring treatment with either&#xD;
             antihistamines or nasal corticosteroids during the grass pollen season.&#xD;
&#xD;
          6. Positive skin prick test response, defined as wheal diameter greater than or equal to&#xD;
             5 mm, to Phleum pratense.&#xD;
&#xD;
          7. Positive specific IgE, defined as greater than or equal to IgE class 2 (0.7 kU/L),&#xD;
             against Phleum pratense.&#xD;
&#xD;
          8. A positive response to the nasal allergen challenge with Phleum pratense, defined as&#xD;
             an increase in TNSS greater than or equal to 5 points.&#xD;
&#xD;
          9. Agree to follow the contraception requirements of the trial as described in Appendix&#xD;
             7.&#xD;
&#xD;
             Female participants must agree to use highly effective contraception as described in&#xD;
             Appendix 7, or must be of non-childbearing potential. A woman is considered to be of&#xD;
             non-childbearing potential if she meets one of the following criteria:&#xD;
&#xD;
               1. post-menopausal (amenorrhea for at least 12 months, and follicle-stimulating&#xD;
                  hormone [FSH] tests at screening confirms post-menopausal status)&#xD;
&#xD;
               2. has no uterus, ovaries or fallopian tubes.&#xD;
&#xD;
         10. The ability to give informed consent and comply with study procedures.&#xD;
&#xD;
         11. Venous access as appropriate for IV dosing, as judged by the investigator or delegate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A prebronchodilator forced expiry volume in 1 second (FEV1) less than 70% of the&#xD;
             predicted value at the screening baseline visit.&#xD;
&#xD;
          2. Clinical history of persistent asthma requiring regular inhaled corticosteroids for &gt;&#xD;
             4 weeks per year outside of the grass pollen season.&#xD;
&#xD;
          3. Clinical history of moderate - severe allergic rhinitis, according to the ARIA&#xD;
             classification, caused by a perennial allergen to which the participant is regularly&#xD;
             exposed.&#xD;
&#xD;
          4. Clinical history of moderate-severe allergic rhinitis, according to the ARIA&#xD;
             classification, caused by tree pollen (those with mild intermittent symptoms not&#xD;
             requiring regular treatment may be included).&#xD;
&#xD;
          5. History of emergency visit or hospital admission for asthma in the previous 12 months.&#xD;
&#xD;
          6. History of chronic obstructive pulmonary disease.&#xD;
&#xD;
          7. History of significant recurrent acute sinusitis, defined as 2 episodes per year for&#xD;
             the last 2 years, all of which required antibiotic treatment.&#xD;
&#xD;
          8. History of chronic sinusitis, defined as sinus symptoms lasting greater than 12 weeks&#xD;
             that includes 2 or more major factors or 1 major factor and 2 minor factors. Major&#xD;
             factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal&#xD;
             discharge or purulence or discolored postnasal discharge, purulence in nasal cavity,&#xD;
             or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis,&#xD;
             fatigue, dental pain, cough, ear pain, pressure, or fullness.&#xD;
&#xD;
          9. History of systemic disease affecting the immune system such as autoimmune diseases,&#xD;
             immune complex disease, or immunodeficiency.&#xD;
&#xD;
         10. At randomization, current symptoms of, or treatment for, upper respiratory tract&#xD;
             infection, acute sinusitis, acute otitis media, or other relevant infectious process;&#xD;
             serous otitis media is not an exclusion criterion. Participants may be re-evaluated&#xD;
             for eligibility after symptoms resolve.&#xD;
&#xD;
         11. Active malignancy at randomization.&#xD;
&#xD;
         12. Any tobacco smoking within the last 6 months or a history of greater than or equal to&#xD;
             10 pack years.&#xD;
&#xD;
         13. Previous treatment by immunotherapy with grass pollen allergen within the previous 5&#xD;
             years.&#xD;
&#xD;
         14. History of bleeding disorders or treatment with anticoagulation therapy.&#xD;
&#xD;
         15. History of anti-IgE monoclonal antibody treatment.&#xD;
&#xD;
         16. Ongoing systemic immunosuppressive treatment.&#xD;
&#xD;
         17. History of intolerance to the study therapy, rescue medications (See Appendix 6), or&#xD;
             their excipients.&#xD;
&#xD;
         18. Pregnant or lactating women. For women of childbearing potential, a positive serum or&#xD;
             urine pregnancy test.&#xD;
&#xD;
         19. The use of any investigational drug within 30 days of the screening visit.&#xD;
&#xD;
         20. The presence of any medical condition that the investigator deems incompatible with&#xD;
             participation in the study.&#xD;
&#xD;
         21. Moderate or severe renal impairment (eGFR &lt;60 mL/min/1.73 m2) or end stage renal&#xD;
             disease.&#xD;
&#xD;
         22. Liver impairment (any abnormal liver function test (ALT, ALK, Bilirubin) at screening.&#xD;
&#xD;
         23. Known or suspected immunosuppression, including history of invasive opportunistic&#xD;
             infections (eg, history of or active tuberculosis, non-tuberculous mycobacterial&#xD;
             infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis,&#xD;
             aspergillosis) despite infection resolution, or otherwise recurrent infections of&#xD;
             abnormal frequency, or prolonged infections suggesting an immunocompromised status, as&#xD;
             judged by the investigator.&#xD;
&#xD;
         24. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at&#xD;
             the pre-study screening assessment that could interfere with the objectives of the&#xD;
             study or the safety of the volunteer.&#xD;
&#xD;
         25. Clinical contraindication to intradermal challenge (IDC), skin prick test (SPT), skin&#xD;
             prick titration (SPT), or nasal allergen challenge (NAC), to include:&#xD;
&#xD;
               1. Previous anaphylactic reaction to grass pollen or extract excipients&#xD;
&#xD;
               2. Acute inflammation of the nose or paranasal sinuses&#xD;
&#xD;
               3. Severe and uncontrolled bronchial asthma or chronic obstructive pulmonary disease&#xD;
&#xD;
               4. Systemic immunotherapy&#xD;
&#xD;
               5. A generalised dermatological condition rendering it impracticable to perform SPT&#xD;
                  or IDC on unaffected skin.&#xD;
&#xD;
               6. Severe dermatographism&#xD;
&#xD;
               7. Unable to cease antihistamines/other interfering drugs (i.e. antidepressants)&#xD;
&#xD;
               8. Persistent severe/unstable asthma&#xD;
&#xD;
               9. Concomitant use of beta-blockers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Myers, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Revolo Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>+ 1.415.728.9922</phone>
    <email>clinicaltrials@revolobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Till, FRCP</last_name>
      <phone>020 7188 2600</phone>
    </contact>
    <investigator>
      <last_name>Prof Till</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

